Edwards Lifesciences Stands Out As US Agency Eyes Broader Access For Heart Valve Device

The Centers for Medicare & Medicaid Services (CMS) proposed removing coverage with evidence development (CED) requirements for Transcatheter Aortic Valve Replacement (TAVR) in symptomatic severe aortic stenosis patients and expanding coverage to asymptomatic cases under CED. Edwards Lifesciences, which holds the only FDA-approved TAVR device for asymptomatic severe aortic stenosis, stands to gain a competitive advantage from these proposed changes. The stock rose 3.74% to $88.65 following the announcement.

06/16/2026, 1:52 PM • Benzinga

Edwards Lifesciences Stock Surges On Heart Valve Devices Growth

Edwards Lifesciences reported strong Q1 2026 earnings, beating consensus on both earnings (78 cents vs. 73 cents) and sales ($1.65B vs. $1.59B). The company saw 16.7% year-over-year sales growth driven by robust demand for heart valve therapies, particularly in TAVR and transcatheter mitral/tricuspid procedures. The company raised its 2026 EPS guidance and widened sales guidance, though Q2 guidance came in slightly below consensus. EW shares surged 4.58% to $83.37.

04/24/2026, 12:50 PM • Benzinga

ORBIMED Advisors Trims $125 Million Terns Stake After a Breakout Year, According to SEC Filing

ORBIMED Advisors LLC reduced its stake in Terns Pharmaceuticals by 5.4 million shares ($125 million) in Q4 2025, though the stock surged 858% over the past year. The clinical-stage biotech company, focused on NASH and metabolic disease treatments, now represents 1.78% of the fund's portfolio. Investors should monitor upcoming clinical trial data to determine if the valuation is justified.

02/20/2026, 12:02 AM • The Motley Fool

Pulmonary Artery Catheter Market Size to Reach USD 1.97 Billion by 2035 Caused by the Surging Critical Care Procedures Globally

The global Pulmonary Artery Catheter Market is valued at USD 1.23 billion in 2025 and is projected to reach USD 1.97 billion by 2035, growing at a CAGR of 4.87%. Growth is driven by increasing critical care procedures, rising cardiovascular disease prevalence, expanding ICU capacities, and demand for precise hemodynamic monitoring. The U.S. market is expected to grow from USD 0.38 billion to USD 0.58 billion during the same period.

02/17/2026, 4:00 AM • GlobeNewswire

Boston Scientific Acquires Penumbra In $14.5 Billion Bet To Dominate Thrombectomy

Boston Scientific agreed to acquire thrombectomy specialist Penumbra for $14.5 billion ($374 per share) in a cash-and-stock deal. Penumbra shareholders will receive approximately 73% cash and 27% equity. The acquisition allows Boston Scientific to enter fast-growing vascular segments. Penumbra reported strong preliminary Q4 2025 results with 21-24% revenue growth. Boston Scientific expects 6-8 cents per share dilution in year one, trending toward neutral to accretive thereafter. The deal is expected to close in 2026.

01/15/2026, 8:42 AM • Benzinga

Court Ruling Ends Edwards Lifesciences $1.2 Billion Plan To Acquire JenaValve

A U.S. District Court granted the FTC's motion to block Edwards Lifesciences' $1.2 billion acquisition of JenaValve Technology, citing concerns that the deal would eliminate competition in the TAVR-AR device market and potentially harm innovation and patient access. Despite the setback, Edwards raised its 2026 adjusted EPS guidance to $2.90-$3.05 and continues advancing its own transcatheter aortic regurgitation valve.

01/12/2026, 9:31 AM • Benzinga

Global Catheters Market Size to Hit USD 55.58 Billion by 2033, Driven by Rising Cardiovascular and Urological Procedures – SNS Insider

The global catheters market is projected to grow from USD 29.17 billion in 2025 to USD 55.58 billion by 2033, with a CAGR of 8.41%. Growth is driven by increasing cardiovascular and urological procedures, aging populations, and technological advancements. However, catheter-associated infections and antibiotic resistance pose challenges. North America dominates with 38.05% market share, while Asia Pacific is the fastest-growing region at 9.23% CAGR.

01/12/2026, 7:52 AM • GlobeNewswire

Transcatheter Heart Valve Replacement Market Size to Reach USD 19.98 Billion by 2033, Growing at a CAGR of 15.32% – SNS Insider

The transcatheter heart valve replacement market is projected to grow from $6.40 billion in 2025 to $19.98 billion by 2033, with a 15.32% CAGR, driven by rising valvular heart disease prevalence and preference for minimally invasive cardiac procedures.

12/17/2025, 10:00 AM • GlobeNewswire

Global Interventional Cardiology Devices Market is Predicted to Cross ~USD 30 Billion by 2034, Due to the Rising Cardiovascular Disease Burden | DelveInsight

The global interventional cardiology devices market is expected to grow from $20 billion in 2024 to $35 billion by 2032, driven by rising cardiovascular disease rates, technological advancements, and increasing adoption of minimally invasive procedures.

12/15/2025, 1:00 PM • GlobeNewswire

EW Investor News: Rosen Law Firm Investigates Breaches of Fiduciary Duties by the Directors and Officers of Edwards Lifesciences Corporation – EW

Rosen Law Firm is investigating potential breaches of fiduciary duties by directors and officers of Edwards Lifesciences Corporation, encouraging shareholders to contact them for more information.

10/27/2025, 8:44 PM • GlobeNewswire

EW Investor News: Rosen Law Firm Investigates Breaches of Fiduciary Duties by the Directors and Officers of Edwards Lifesciences Corporation – EW

Rosen Law Firm is investigating potential breaches of fiduciary duties by directors and officers of Edwards Lifesciences Corporation, encouraging shareholders to seek more information.

10/15/2025, 5:58 PM • GlobeNewswire

EW 投資者消息：若您因 Edwards Lifesciences Corporation (NYSE: EW) 蒙受損失，請聯絡 Rosen Law Firm 了解您的權益

Rosen Law Firm is investigating potential breaches of fiduciary duty by Edwards Lifesciences Corporation's directors and senior management, encouraging current shareholders to seek more information.

10/03/2025, 12:16 PM • GlobeNewswire

EW Investor News: If You Have Suffered Losses in Edwards Lifesciences Corporation (NYSE: EW), You Are Encouraged to Contact The Rosen Law Firm About Your Rights

Rosen Law Firm is investigating potential breaches of fiduciary duties by directors and officers of Edwards Lifesciences Corporation, encouraging shareholders to contact them for more information.

10/02/2025, 3:45 PM • GlobeNewswire

EW Investor News: If You Have Suffered Losses in Edwards Lifesciences Corporation (NYSE: EW), You Are Encouraged to Contact The Rosen Law Firm About Your Rights

Rosen Law Firm is investigating potential breaches of fiduciary duties by directors and officers of Edwards Lifesciences Corporation, encouraging shareholders who have suffered losses to contact them.

09/26/2025, 7:04 PM • GlobeNewswire

JenaValve Announced ESC Guidelines Recognize TAVI as Class IIb Recommendation for Aortic Regurgitation

European Society of Cardiology guidelines now recommend transcatheter aortic valve implantation (TAVI) as a treatment option for patients with severe, symptomatic aortic regurgitation who are ineligible for surgery.

09/10/2025, 8:00 AM • GlobeNewswire